Primary chemotherapy with sequential docetaxel fallowed by docetaxel and epirubicin in large operable breast cancer

Primary chemotherapy is increasingly used in patients with large operable breast cancer. Docetaxel and epirubicin are the most active agents in breast cancer treatment.

Purpose: To evaluate clinical response rate, breast conserving surgery and pathological response rate in patients with large operable breast cancer treated with docetaxel followed by docetaxel and epirubicin as primary chemotherapy.

Patients and methods: Patients with operable breast cancer more than 3 cm in the longest diameter with T2N0, T2N1 and T3N0 disease were enrolled. Patients were treated with three cycles of docetaxel 100 mg/m2 followed by three cycles of docetaxel 75 mg/m2 and epirubicin 90 mg/m2 prior to surgery.

Results: Sixty-five patients were enrolled between 09/2002 and 12/2005. The median age was 48.9 years and 72.3% were premenopausal. Median tumour size was 4.26 cm, 10.8% were T3 tumours and 38.5% had clinical positive lymph nodes. Of the tumours 58.5% were grade 1/2, 33.9% ER positive and 21.5% c-erb negative. All six cycles were administered to 62 patients; six cycles were delayed and five had dose reductions. Complete clinical response occurred in 41.5% of patients and partial response in 49.2%. Breast conserving surgery was performed in 30% of patients however it was feasible in 57%. Complete pathological response occurred in both primary tumour and nodes in 28%, and in 34% just in the primary tumour. Nine percent of cases had neutropenia and 7.7% febrile neutropenia, and two cases had a hypersensitivity reaction to docetaxel. One associated treatment death occurred.

Conclusion: Docetaxel followed by epirubicin and docetaxel as primary chemotherapy results in a high clinical and pathological response rate. The majority of adverse events were predictable and manageable.

Operable breast cancer; Primary chemotherapy

[1] Goldhirsch A., Glick J.H., Gelber R.D. et al.: " Meeting highlights international expert consensus on the primary therapy of early breast cancer 2005". Ann. Oneal., 2005, 16, 1569.

[2] Fisher B., Bryant J., Wolmark N. et al.: "Effect of preoperative chemotherapy on the outcome of women with operable breast cancer". J. Clin. Oneal., 1998, 16, 2672.

[3] Puglisi F., Mansutti M., Aprile G. et al.: "Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer". Anticancer Res., 2004, 24, 2487.

[4] Mano M.S., Awada A.: "Primary chemotherapy for breast cancer: the evidence and the future". Ann. Oneal., 2004, 15, 1161.

[5] Therasse P., Arbuck S.G., Eisehauer E.A. et al.: "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada". J. Natl. Cancer Inst., 2000, 92, 205.

[6] Fisher B., Brown A., Mamounas E. et al.: "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18". 1. Clin. Oneal., 1997, 15, 2483.

[7] Valero V.: "Primary chemotherapy with docetaxel for the management of breast cancer". Oncology, 2002, 16, 35.

[8] Bear H.D., Anderson S., Brown A. et al.: "The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxornbicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27". 1. Clin. Oncol., 2003, 21, 4165.

[9] O'Regan R.M.U., Sparano J. et al.: "Final results of a phase II study of neo-adjuvant docetaxel, doxorrnbicin and cyclophosphamide (TAC) in Stage III breast cancer". Proc. Am. Soc. Clin. Oncol., 2003, 22, 41.

[10] Heys S.D., Hutcheon A.W., Sarkar T.K. et al.: "Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial". Clin. Breast Cancer, 2002, 3 (suppl. 2), S69.

[11] Nabholtz J.M., Senn H.J., Bezwoda W.R. et al.: "Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group". 1. Clin Oncol., 1999, 17, 1413.

[12] Chan S., Friedrichs K., Noel D. et al.: "Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer". 1. Clin. Oncol., 1999, 17, 2341.

[13] ten Bokkel Huinink W.W., Prove A.M., Piccart M. et al.: "A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group". Ann. Oncol., 1994, 5, 527.

[14] Valero V., Holmes F.A., Walters R.S. et al.: "Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer". 1. Clin. Oncol., 1995, 13, 2886.

[15] Mauriac L., Durand M., Avril A. et al.: "Effects of pnmary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre". Ann. Oncol., 1991, 2, 347.

[16] Makris A., Powles T.J., Ashley S.E. et al.: "A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer". Ann. Oncol., 1998, 9, 1179.

[17] Steger G.G. WC, Schimidinger M. et al.: "Predictive factors of complete pathological response in primery breast cancer treated noeadjuvantly with epirnbicin/taxan +G-CSF regimen". Proc. Am. Soc. Clin. Oncol., 2001, 29, 39 (abstr. 154).

[18] Zhang F., Pusztai L., Yang Y. et al.: "Correlation between HER2 expression of breast cancer and response in neo-adjuvant FAC chemotherapy". Proc. Am. Soc. Clin. Oncol., 2002, 21, 32a (abstr. 124).

[19] Makris A., Powles T.J., Dowsett M. et al.: "Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas". Clin. Cancer Res., 1997, 3, 593.

[20] Kuerer H.M., Newman L.A., Smith T.L. et al.: "Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy". 1. Clin. Oncol., 1999, 17, 460.

[21] Mauriac L., MacGrogan G., Avril A. et al.: "Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. lnstitut Bergonie Bordeaux Groupe Sein (IBBGS)". Ann. Oncol., 1999, 47.